Home LiteratureArticle Details
PMID: 26079100 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

The hypoxic tumor microenvironment: A driving force for breast cancer progression.

Biochimica et biophysica acta ·Vol. 1863 ·No. 3 ·2016-03-00 ·Pages 382-391

Semenza GL

Abstract

Intratumoral hypoxia is a common finding in breast cancer and is associated with a significantly increased risk of metastasis and patient mortality. Hypoxia-inducible factors activate the transcription of a large battery of genes encoding proteins that promote primary tumor vascularization and growth, stromal cell recruitment, extracellular matrix remodeling, premetastatic niche formation, cell motility, local tissue invasion, extravasation at sites of metastasis, and maintenance of the cancer stem cell phenotype that is required to generate secondary tumors. Recent preclinical studies suggest that the combination of cytotoxic chemotherapy with drugs that inhibit hypoxia-inducible factors may improve outcome for women with triple-negative breast cancer. This article is part of a Special Issue entitled: Tumor Microenvironment Regulation of Cancer Cell Survival, Metastasis, Inflammation, and Immune Surveillance edited by Peter Ruvolo and Gregg L. Semenza.

Keywords
Bone metastasis Lung metastasis Lymph node metastasis Mesenchymal stem cells Microvesicles Myeloid-derived suppressor cells Tumor-associated macrophages
MeSH Terms
Breast Neoplasms/metabolism,pathology,therapy Cell Hypoxia Cell Movement Disease Progression Female Humans Hypoxia-Inducible Factor 1/metabolism Models, Biological Tumor Microenvironment
Chemicals
Hypoxia-Inducible Factor 1
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Semenza Gregg L
Vascular Program, Institute for Cell Engineering Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: gsemenza@jhmi.edu.
References (105)
105 references, click to expand
  1. Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes.
    Oncogene. 2014 Sep 11;33(37):4613-22 PMID: 24662828
  2. Collagen prolyl hydroxylases are essential for breast cancer metastasis.
    Cancer Res. 2013 Jun 1;73(11):3285-96 PMID: 23539444
  3. RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease.
    Int J Mol Med. 2008 Jul;22(1):25-31 PMID: 18575772
  4. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Cancer Res. 2007 May 1;67(9):4157-63 PMID: 17483326
  5. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes.
    Mol Cell Proteomics. 2010 Jun;9(6):1085-99 PMID: 20124223
  6. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.
    Cancer Res. 2005 Jul 1;65(13):5506-11 PMID: 15994920
  7. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Oncotarget. 2015 Feb 10;6(4):2250-62 PMID: 25544770
  8. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy.
    Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17460-5 PMID: 23033492
  9. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs.
    Oncogene. 2012 Apr 5;31(14):1757-70 PMID: 21860410
  10. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.
    Int J Cancer. 2005 Sep 20;116(5):734-9 PMID: 15849727
  11. Lysine post-translational modifications of collagen.
    Essays Biochem. 2012;52:113-33 PMID: 22708567
  12. Hypoxic enhancement of exosome release by breast cancer cells.
    BMC Cancer. 2012;12:421 PMID: 22998595
  13. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
    Cancer Cell. 2009 Jun 2;15(6):501-13 PMID: 19477429
  14. Lysyl oxidase is essential for hypoxia-induced metastasis.
    Nature. 2006 Apr 27;440(7088):1222-6 PMID: 16642001
  15. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors.
    Cancer Res. 2004 Dec 1;64(23):8585-94 PMID: 15574765
  16. Hypoxia affects tumor cell invasiveness in vitro: the role of hypoxia-activated ligand HAL1/13 (Ku86 autoantigen).
    Cancer Lett. 2000 Jun 30;154(2):163-74 PMID: 10806304
  17. Breast tumor cell lines from pleural effusions.
    J Natl Cancer Inst. 1974 Sep;53(3):661-74 PMID: 4412247
  18. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.
    PLoS One. 2009;4(9):e6896 PMID: 19727403
  19. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.
    Genes Dev. 2012 Jun 15;26(12):1287-99 PMID: 22713869
  20. Detection and characterization of tumor hypoxia using pO2 histography.
    Antioxid Redox Signal. 2007 Aug;9(8):1221-35 PMID: 17536958
  21. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.
    Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7 PMID: 23589885
  22. Hypoxia-inducible factors in physiology and medicine.
    Cell. 2012 Feb 3;148(3):399-408 PMID: 22304911
  23. Crosstalk of Oncogenic Signaling Pathways during Epithelial-Mesenchymal Transition.
    Front Oncol. 2014 Dec 11;4:358 PMID: 25566498
  24. The pre-metastatic niche: finding common ground.
    Cancer Metastasis Rev. 2013 Dec;32(3-4):449-64 PMID: 23636348
  25. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
    Nat Med. 2012 Jun;18(6):883-91 PMID: 22635005
  26. A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment.
    Lab Chip. 2012 Nov 21;12(22):4855-63 PMID: 23023115
  27. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis.
    Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3234-42 PMID: 24938788
  28. The extracellular matrix: a dynamic niche in cancer progression.
    J Cell Biol. 2012 Feb 20;196(4):395-406 PMID: 22351925
  29. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
    Breast Cancer Res Treat. 2008 Aug;110(3):465-75 PMID: 17805961
  30. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation.
    Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74 PMID: 21911388
  31. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
    J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 PMID: 11181778
  32. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.
    Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2784-9 PMID: 22308314
  33. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
    Clin Cancer Res. 2006 Aug 1;12(15):4562-8 PMID: 16899602
  34. Lymphangiogenesis and lymphatic metastasis in breast cancer.
    Pathophysiology. 2010 Sep;17(4):229-51 PMID: 20036110
  35. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
    Cancer Cell. 2003 Apr;3(4):347-61 PMID: 12726861
  36. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.
    Cancer Res. 2007 Jan 15;67(2):563-72 PMID: 17234764
  37. Tumor-associated macrophages: from mechanisms to therapy.
    Immunity. 2014 Jul 17;41(1):49-61 PMID: 25035953
  38. A tense situation: forcing tumour progression.
    Nat Rev Cancer. 2009 Feb;9(2):108-22 PMID: 19165226
  39. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
    Nature. 2005 Dec 8;438(7069):820-7 PMID: 16341007
  40. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2.
    Physiol Rev. 2012 Jul;92(3):967-1003 PMID: 22811423
  41. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer.
    Int J Oncol. 2008 Sep;33(3):585-93 PMID: 18695890
  42. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
    Cell Stem Cell. 2007 Nov;1(5):555-67 PMID: 18371393
  43. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells.
    Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8 PMID: 19168635
  44. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?
    Cancer Res. 2009 Jul 1;69(13):5292-3 PMID: 19549886
  45. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion.
    Cancer Metastasis Rev. 2009 Jun;28(1-2):65-76 PMID: 19160018
  46. Prolyl 4-hydroxylase.
    Crit Rev Biochem Mol Biol. 2010 Apr;45(2):106-24 PMID: 20199358
  47. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.
    Cancer Cell. 2009 Jan 6;15(1):35-44 PMID: 19111879
  48. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.
    Oncogene. 2010 Feb 4;29(5):625-34 PMID: 19946328
  49. The hippo signaling pathway in development and cancer.
    Dev Cell. 2010 Oct 19;19(4):491-505 PMID: 20951342
  50. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers.
    Cancer Res. 2007 Apr 1;67(7):3441-9 PMID: 17409455
  51. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.
    Mol Cell Biol. 1996 Sep;16(9):4604-13 PMID: 8756616
  52. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
    Clin Cancer Res. 2002 Jun;8(6):1831-7 PMID: 12060624
  53. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
    Blood. 2014 Dec 11;124(25):3748-57 PMID: 25320245
  54. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
    Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):E3367-76 PMID: 23129632
  55. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.
    J Mol Med (Berl). 2012 Jul;90(7):803-15 PMID: 22231744
  56. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.
    Cancer Res. 2003 Mar 1;63(5):1138-43 PMID: 12615733
  57. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation.
    Jpn J Cancer Res. 1997 Jun;88(6):590-9 PMID: 9263537
  58. Targeting HIF-1 for cancer therapy.
    Nat Rev Cancer. 2003 Oct;3(10):721-32 PMID: 13130303
  59. Hypoxia--a key regulatory factor in tumour growth.
    Nat Rev Cancer. 2002 Jan;2(1):38-47 PMID: 11902584
  60. The actin cytoskeleton in cancer cell motility.
    Clin Exp Metastasis. 2009;26(4):273-87 PMID: 18498004
  61. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype.
    Oncotarget. 2014 Dec 30;5(24):12509-27 PMID: 25587023
  62. The structure of fibrous proteins of the collagen-gelatin group.
    Proc Natl Acad Sci U S A. 1951 May;37(5):272-81 PMID: 14834150
  63. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells.
    Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13147-52 PMID: 21788507
  64. Therapeutic targets in triple negative breast cancer.
    J Clin Pathol. 2013 Jun;66(6):530-42 PMID: 23436929
  65. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    J Mol Med (Berl). 2014 Feb;92(2):151-64 PMID: 24248265
  66. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression.
    Nat Med. 2011 Mar;17(3):320-9 PMID: 21383745
  67. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop.
    Cancer Res. 2005 Jun 15;65(12):5278-83 PMID: 15958574
  68. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells.
    Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2707-16 PMID: 23012449
  69. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway.
    Blood. 1998 May 1;91(9):3300-7 PMID: 9558386
  70. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.
    Cancer Res. 2004 Oct 1;64(19):7022-9 PMID: 15466195
  71. Tumor hypoxia and malignant progression.
    Methods Enzymol. 2004;381:335-54 PMID: 15063685
  72. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer.
    Eur J Cancer. 2013 Jul;49(11):2608-18 PMID: 23566416
  73. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.
    Cell. 2008 Apr 4;133(1):66-77 PMID: 18394990
  74. Hypoxia: a key regulator of angiogenesis in cancer.
    Cancer Metastasis Rev. 2007 Jun;26(2):281-90 PMID: 17603752
  75. Comprehensive molecular portraits of human breast tumours.
    Nature. 2012 Oct 4;490(7418):61-70 PMID: 23000897
  76. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
    Breast Cancer Res. 2012;14(1):R6 PMID: 22225988
  77. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
    Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38 PMID: 25453096
  78. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors.
    Int J Cancer. 2009 Oct 1;125(7):1595-603 PMID: 19462451
  79. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis.
    J Clin Invest. 2013 Jan;123(1):189-205 PMID: 23318994
  80. Rab27a and Rab27b control different steps of the exosome secretion pathway.
    Nat Cell Biol. 2010 Jan;12(1):19-30; sup pp 1-13 PMID: 19966785
  81. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells.
    Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):E384-93 PMID: 24324133
  82. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
    Mol Cell. 2008 May 23;30(4):393-402 PMID: 18498744
  83. Exosomes in tumor microenvironment influence cancer progression and metastasis.
    J Mol Med (Berl). 2013 Apr;91(4):431-7 PMID: 23519402
  84. Hypoxia-inducible factor 1 and cardiovascular disease.
    Annu Rev Physiol. 2014;76:39-56 PMID: 23988176
  85. Cancer genome landscapes.
    Science. 2013 Mar 29;339(6127):1546-58 PMID: 23539594
  86. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.
    Nature. 2007 Oct 4;449(7162):557-63 PMID: 17914389
  87. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells.
    Cell. 2011 Nov 11;147(4):759-72 PMID: 22078877
  88. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Cancer. 2003 Mar 15;97(6):1573-81 PMID: 12627523
  89. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment.
    Proc Natl Acad Sci U S A. 2014 May 20;111(20):E2120-9 PMID: 24799675
  90. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis.
    Mol Cancer Res. 2013 May;11(5):456-66 PMID: 23378577
  91. Vesicle trafficking and RNA transfer add complexity and connectivity to cell-cell communication.
    Cancer Res. 2013 Jun 1;73(11):3200-5 PMID: 23695552
  92. A decade of exploring the cancer epigenome - biological and translational implications.
    Nat Rev Cancer. 2011 Oct;11(10):726-34 PMID: 21941284
  93. Extending survival with chemotherapy in metastatic breast cancer.
    Oncologist. 2005;10 Suppl 3:20-9 PMID: 16368868
  94. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
    Cancer Res. 2013 Sep 15;73(18):5810-20 PMID: 23928995
  95. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent.
    Clin Cancer Res. 2004 Dec 1;10(23):7972-7 PMID: 15585632
  96. Hypoxia and the extracellular matrix: drivers of tumour metastasis.
    Nat Rev Cancer. 2014 Jun;14(6):430-9 PMID: 24827502
  97. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.
    Nat Cell Biol. 2015 Jan;17(1):95-103 PMID: 25438054
  98. Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients.
    Arch Med Res. 2013 Apr;44(3):208-14 PMID: 23506723
  99. The hypoxic tumour microenvironment and metastatic progression.
    Clin Exp Metastasis. 2003;20(3):237-50 PMID: 12741682
  100. An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity.
    Cell Adh Migr. 2012 May-Jun;6(3):236-48 PMID: 22863741
  101. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1.
    J Biol Chem. 2010 Feb 26;285(9):6658-69 PMID: 20026874
  102. Accessories to the crime: functions of cells recruited to the tumor microenvironment.
    Cancer Cell. 2012 Mar 20;21(3):309-22 PMID: 22439926
  103. Guiding cell migration by tugging.
    Curr Opin Cell Biol. 2013 Oct;25(5):619-26 PMID: 23830911
  104. Oxygen tension regulates the expression of a group of procollagen hydroxylases.
    Eur J Biochem. 2003 Nov;270(22):4515-22 PMID: 14622280
  105. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review.
    Cancer Metastasis Rev. 2013 Dec;32(3-4):623-42 PMID: 23709120
Article Info
Journal
Biochimica et biophysica acta
Abbr.
Biochim Biophys Acta
ISSN
0006-3002
DOI
10.1016/j.bbamcr.2015.05.036
Email
gsemenza@jhmi.edu
Published
2016-03-00
Epub
2015-00-14
Pages
382-391
Language
English
Region
Netherlands
NLM ID
0217513
PMCID
PMC4678039
Subset
IM
Grants
NCI NIH HHS · U54 CA143868 · United States
External Links
PubMed source DOI: 10.1016/j.bbamcr.2015.05.036 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2